Digoxin (NSC 95100)

For research use only.

Catalog No.S4290

6 publications

Digoxin (NSC 95100) Chemical Structure

CAS No. 20830-75-5

Digoxin (NSC 95100) is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.

Selleck's Digoxin (NSC 95100) has been cited by 6 publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Digoxin (NSC 95100) is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.
Targets
Na,K-ATPase α2β3 [1]
()
Na,K-ATPase α2β1 [1]
()
Na,K-ATPase α1β1 [1]
()
42.8 nM(Ki) 58.7 nM(Ki) 268 nM(Ki)
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
rat hepatocytes NXj0RnE2TnWwY4Tpc44h[XO|YYm= M2ftU2RzfWdidYD0ZYtmKGmwIILheEBp\XCjdH;jfZRmeyxiS329NE4yQCEQvF2= NYqw[|RxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5NlY3OTlpPkKwPVI3PjF7PD;hQi=>
human hepatocytes MmWwSpVv[3Srb36gZZN{[Xl? MmTZNE4xPSC2bzCxNEB2VQ>? M4P5cGRzfWdidYD0ZYtmKGmwIIPhcoR4cWOqLXP1cJR2emWmIHj1cYFvKGincHH0c4N6fGW|IHH0JFAvODVidH:gNVAhfU1iYYSgN|ch\GWpQzDifUBOcWOqYXXsbZMuVWWwdHXuJItqdmW2aXPzM5NkcW62aXzsZZRqd25ic4DlZ5Rzd3Olb4D5MEBMdT1{LkO5JO69VQ>? NVTOW4dHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5NlY3OTlpPkKwPVI3PjF7PD;hQi=>
LLC-PK1 NHGwV|RHfW6ldHnvckBie3OjeR?= NHjBdXhVWF:WUlHOV3BQWlSHUkqgbY5pcWKrdHnvckBw\iCHMkG3ZoV1[UdidYD0ZYtmKGmwIF;heJAzNWW6cILld5NqdmdiTFzDMXBMOSClZXzsd{whU2l;MD6wN|fPxE1? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTRyOEW1O{c,OTF2MEi1OVc9N2F-
High Five (BTI-TN5B1-4) M3PkWmZ2dmO2aX;uJIF{e2G7 MYLUVH9VWkGQU2DPVnRGWjpiQWTQJIh6\HKxbInzbZMhcW5ibXXtZpJidmViZoLhZ5Rqd25iZoLvcUBJcWeqIF\peoUhMEKWST3UUlVDOS12KTDj[YxteyxiS329NlUvQc7:TR?= NYewOVBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3PFU3QDRpPkGxO|g2Pjh2PD;hQi=>
LLC-PK1 MWPGeY5kfGmxbjDhd5NigQ>? Mnz3WHBgXFKDTmPQU3JVTVJ8IHnubIljcXSrb36gc4YhXGG3cn;jbI9t[XSnIIXweIFs\SCrbjDPZZRxOi2neIDy[ZN{cW6pIFzMR{1RUzFiY3XscJMtKEurPUCuOVjPxE1? Ml3LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5OUK2PVQoRjFzN{myOlk1RC:jPh?=
LLC-PK1 MnPqSpVv[3Srb36gZZN{[Xl? NVXzfHJUXFChVGLBUnNRV1KWRWK6JJVxfGGtZTDpckBQ[XSyMj3lfJBz\XO|aX7nJGxNSy2SS{GgZ4VtdHNuIFvtQVEvODgQvF2= M4\5XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzN{myOlk1Lz5zMUe5NlY6PDxxYU6=
LLC-PK1 MoLvSpVv[3Srb36gZZN{[Xl? NIDXXpZVWF:WUlHOV3BQWlSHUkqgeZB1[WunIHnuJG9ifHB{LXX4dJJme3OrbnegUGxENVCNMTDj[YxteyxiS329NE4zPzoQvF2= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTh6M{[0NUc,OTF6OEO2OFE9N2F-
MDCK NETmTWdHfW6ldHnvckBie3OjeR?= NGfHWoVVWF:WUlHOV3BQWlSHUkqgZ4VtdCCjY3P1cZVt[XSrb36gbY4hV0GWUETDNU1mgHC{ZYPzbY5oKE2GQ1ugZ4VtdHNuIFvtQVcvQM7:TR?= M1jSSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2OUmzOlA1Lz5zNEm5N|YxPDxxYU6=
MDCK MVTGeY5kfGmxbjDhd5NigQ>? M4HRTnRRZ1SUQV7TVG9TXEWUOjDj[YxtKGGlY4XteYxifGmxbjDpckBQSVSSNFOxMYV5eHKnc4PpcochVUSFSzDj[YxteyxiS329PO69VQ>? NHnmUYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEm5N|YxPCd-MUS5PVM3ODR:L3G+
TK10 MnPBR5l1d3SxeHnjbZR6KGG|c3H5 M{\JblQ5KGi{cx?= MoC2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWGsyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNFE1Ps7:TR?= Mn75QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ|MEmzNVUoRjF4M{C5N|E2RC:jPh?=
MCF7 NXz1OlRZS3m2b4TvfIlkcXS7IHHzd4F6 NWXpNIo1PDhiaILz M4XN[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlAzPDIQvF2= M2PWUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4M{C5N|E2Lz5zNkOwPVMyPTxxYU6=
K562 MYHDfZRwfG:6aXPpeJkh[XO|YYm= MnK4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsd{BjgSC[VGSgZZN{[XluIFnDOVA:OC5yMkiy{txO MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjNyOUOxOUc,OTZ|MEmzNVU9N2F-
UACC62 NUfmOpJpS3m2b4TvfIlkcXS7IHHzd4F6 M3SzZVQ5KGi{cx?= M1XkNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHVCS0N4MjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvODJ7Nd88US=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjNyOUOxOUc,OTZ|MEmzNVU9N2F-
HeLa M4PJdmN6fG:2b4jpZ4l1gSCjc4PhfS=> MlqyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGRPSSC{ZYDsbYNifGmxbjDifUBqdWGpaX7nJIFv[Wy7c3nz Mm\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyNk[wOVUoRjF6ME[2NFU2RC:jPh?=
HeLa MVnGeY5kfGmxbjDhd5NigQ>? MnjETY5pcWKrdHnvckBw\iCvaYTvd4l{KGmwIHj1cYFvKEinTHGgZ4VtdHNiYomgbY1i\2mwZzDhcoFtgXOrcx?= NXLrN4Z{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwOlYxPTVpPkG4NFY3ODV3PD;hQi=>
colon cancer NVrzZnFYS3m2b4TvfIlkcXS7IHHzd4F6 NWLkbJR5PzJiaILz NXGwbGk3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFczKGi{czDifUBHVUODIH3leIhw\CxiSVO1NF0xNjIQvF2= NEnCPII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi5OFc{Oyd-MUm4PVQ4OzN:L3G+
CC20 M33ncmN6fG:2b4jpZ4l1gSCjc4PhfS=> NWrvUnhkPzJiaILz MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDR|IxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDGUWNCKG2ndHjv[EwhUUN3ME2wMlI1|ryP M4\C[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEm0O|M{Lz5zOUi5OFc{OzxxYU6=
HCT116 MoixR5l1d3SxeHnjbZR6KGG|c3H5 NVX3blg3PzJiaILz MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGZOS0FibXX0bI9lNCCLQ{WwQVAvOjgQvF2= M1\YZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEm0O|M{Lz5zOUi5OFc{OzxxYU6=
HT-29 NHK3e5ZEgXSxdH;4bYNqfHliYYPzZZk> M2LmTVczKGi{cx?= Ml3oR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGZOS0FibXX0bI9lNCCLQ{WwQVEvPM7:TR?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh7NEezN{c,OTl6OUS3N|M9N2F-
Hs578Bst M3T4XmN6fG:2b4jpZ4l1gSCjc4PhfS=> NE\FWI84OiCqcoO= NYKxNYhmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHN3N{jCd5Qh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGlEPTB;MD6wOO69VQ>? NGCzNVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOlE3QCd-MkKzNVYyPjh:L3G+
Hs578T NIXJfXhEgXSxdH;4bYNqfHliYYPzZZk> NWi1OZVSPzJiaILz MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDId|U4QFRiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUC9NE4zPTIQvF2= NELCU4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOlE3QCd-MkKzNVYyPjh:L3G+
T47D M1\CUGN6fG:2b4jpZ4l1gSCjc4PhfS=> M1P4NVczKGi{cx?= MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBKSzVyPUCuOlbPxE1? M{TCeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{G2NVY5Lz5{MkOxOlE3QDxxYU6=
SK-BR-3 M3\SWmN6fG:2b4jpZ4l1gSCjc4PhfS=> MVW3NkBpenN? MlnTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2suSlJvMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiSVO1NF0yNjB6zszN NH3PT289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOlE3QCd-MkKzNVYyPjh:L3G+
MCF7 MULDfZRwfG:6aXPpeJkh[XO|YYm= MkL2O|IhcHK| MoDQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3ME20MlfPxE1? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNkG2PEc,OjJ|MU[xOlg9N2F-
Hs578Bst MYXDfZRwfG:6aXPpeJkh[XO|YYm= NInZV4o1OCC3TR?= M{TodVczKGi{cx?= MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDId|U4QEK|dDDj[YxteyCjdDC0NEB2VSCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbDygTWM2OD12Nz63{txO MnzpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MU[xOlgoRjJ{M{G2NVY5RC:jPh?=
CHO MlLGSpVv[3Srb36gZZN{[Xl? MXrwTWM2OCC4YXz1[ZMh\m:{IIPv[Il2dSCobIXvdoV{[2WrbjCoNVAhfU1rIIXweIFs\SCrbjDPRXRROUJzLYTyZY5{\mWldHXkJGNJVyClZXzsd{whUUN3ME2zMlI{PTl2zszN NIPiPXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3NVQyPSd-MkO1O|E1OTV:L3G+
CHO M4rZVGZ2dmO2aX;uJIF{e2G7 NEHyV|dxUUN3MDD2ZYx2\XNiZn;yJJNw\Gm3bTDmcJVwemW|Y3XpckApOTBidV2pJJVxfGGtZTDpckBQSVSSMVKzMZRz[W6|ZnXjeIVlKEOKTzDj[YxteyxiSVO1NF0yOy5zOEK2{txO NFPrbmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3NVQyPSd-MkO1O|E1OTV:L3G+
Hs683 MVPDfZRwfG:6aXPpeJkh[XO|YYm= NGSwXYI{KGSjeYO= MmjzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTJM3QDNiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlA1|ryP NVvGOoxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFYxODVpPkKzO|A3ODB3PD;hQi=>
A549 M3TjcGN6fG:2b4jpZ4l1gSCjc4PhfS=> MV[zJIRigXN? M{XUcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlA2|ryP M3O3[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{C2NFA2Lz5{M{ewOlAxPTxxYU6=
PC3 M3\UO2N6fG:2b4jpZ4l1gSCjc4PhfS=> MUmzJIRigXN? NIXzRppEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlA4Pc7:TR?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyNkCwOUc,OjN5ME[wNFU9N2F-
U373 M2SzNmN6fG:2b4jpZ4l1gSCjc4PhfS=> MWezJIRigXN? NH2zeopEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOzd|IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NE4yPDcQvF2= MkfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[wNFUoRjJ|N{C2NFA2RC:jPh?=
SK-MEL-28 M2f5OWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2jmT|Mh\GG7cx?= M1TsUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU2HTD2yPEBk\WyuczDh[pRmeiB|IHThfZMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMk[2{txO NYfBfVhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFYxODVpPkKzO|A3ODB3PD;hQi=>
MCF7 MoGzR5l1d3SxeHnjbZR6KGG|c3H5 MlT4N{Bl[Xm| M3y5e2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQzPs7:TR?= MmDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[wNFUoRjJ|N{C2NFA2RC:jPh?=
Drosophila Schneider cells MmjzSpVv[3Srb36gZZN{[Xl? MkfFRY51[WexbnnzeEBi[3Srdnn0fUBifCC2cnHud4FkfGm4YYTpc44h\G:vYXnuJI9nKFKRUnfhcY1ifCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDEdo9{d3CqaXzhJHNkcG6naXTldkBk\WyuczDjc{1mgHC{ZYPzbY5oKEejbEStSG5CKGKrbnTpcoch\G:vYXnuMEBKSzVyPUNOwG0> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2MES4Okc,OjRyNEC0PFY9N2F-
Drosophila Schneider cells M13ZbmZ2dmO2aX;uJIF{e2G7 NIXSZXNCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IITyZY5{[WO2aY\heIlwdiCmb33hbY4hd2ZiUl;S[4FudWG2IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGRzd3OxcHjpcIEhW2OqbnXp[IVzKGOnbHzzJINwNWW6cILld5NqdmdiR3HsOE1FVkFiYnnu[Ilv\yCmb33hbY4tKEmFNUC9Nu69VQ>? M2TyS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESwOFg3Lz5{NEC0NFQ5PjxxYU6=
RKO-AS45-1 NFrITYdEgXSxdH;4bYNqfHliYYPzZZk> M2LGXVQ5KGi{cx?= M37ZXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJMVy2DU{S1MVEh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkSy{txO MmPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkK3O|IoRjJ4MUKyO|czRC:jPh?=
HeLa Ml3YR5l1d3SxeHnjbZR6KGG|c3H5 MVq0PEBpenN? MoThR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKuNu69VQ>? NGHie5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa MnuxSpVv[3Srb36gZZN{[Xl? NGfyfHgyPTBibl2= MlLkNlQhcHK| MVnJcohq[mm2aX;uJI9nKE6jKDupM2spMyliQWTQZZNmKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYSgNVUxKG6PIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> NF:yV5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa MYrGeY5kfGmxbjDhd5NigQ>? M3O4U|E2OCCwTR?= M{WzSVI1KGi{cx?= Mn3wTY5pcWKrdHnvckBw\iCQYTirLU9MMCtrIFHUVIF{\SCrbjDoeY1idiCKZVzhJINmdGy|IHH0JFE2OCCwTTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdITpcoc> NF7meGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa M{\qeWZ2dmO2aX;uJIF{e2G7 MlW0NVUxKG6P NX;HSWFoOjRiaILz NGX3Z45KdmirYnn0bY9vKG:oIF7hLEsqN0tqKzmgRXRR[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOTVyIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? M2D6elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUKyO|czLz5{NkGyNlc4OjxxYU6=
HeLa Mn7qSpVv[3Srb36gZZN{[Xl? NYL1UpFZOTVyIH7N MYiyOEBpenN? NVT6eFVjUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? NFfFRmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa NFrwR2NHfW6ldHnvckBie3OjeR?= NITVS5QyPTBibl2= M{DVU|I1KGi{cx?= NES4OGdKdmirYnn0bY9vKG:oIF7hLEsqN0tqKzmgRXRR[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOTVyIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{Mke3Nkc,OjZzMkK3O|I9N2F-
HeLa M2DkZmZ2dmO2aX;uJIF{e2G7 MnLkNVUxKG6P Mo\GNlQhcHK| MUXJcohq[mm2aX;uJI9nKE6jKDupM2spMyliQWTQZZNmKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYSgNVUxKG6PIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> NE\mPJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa MYDGeY5kfGmxbjDhd5NigQ>? MVexOVAhdk1? MYCyOEBpenN? NXHrUIxxUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? NEnPe2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa MnjzSpVv[3Srb36gZZN{[Xl? M{fWclE2OCCwTR?= M4O3Z|I1KGi{cx?= M3;sOmlvcGmkaYTpc44hd2ZiTnGoL{kwUyhtKTDBWHBie2ViaX6gbJVu[W5iSHXMZUBk\WyuczDheEAyPTBibl2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5o NXzWNIJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
Kasumi-1 M1P1VmN6fG:2b4jpZ4l1gSCjc4PhfS=> M1fpbFQ5KGi{cx?= MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLZZN2dWlvMTDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNiYYPzZZktKEmFNUC9NE4xQTQQvF2= MmnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OEO4OFIoRjJ5OUizPFQzRC:jPh?=
MV4-11 NXPTd3FPS3m2b4TvfIlkcXS7IHHzd4F6 NYfFZnl3PDhiaILz MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNVEy|ryP NH7qZYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m4N|g1Oid-Mke5PFM5PDJ:L3G+
HT-29 NYTr[IExS3m2b4TvfIlkcXS7IHHzd4F6 M{HwfVczKGi{cx?= Mni3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuN|jPxE1? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl6M{i0Nkc,Ojd7OEO4OFI9N2F-
H1299 MUXDfZRwfG:6aXPpeJkh[XO|YYm= MXWyOEBpenN? M2TEOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGgyOjl7IHPlcIx{KGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQ3|ryP M4XuflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUizPFQzLz5{N{m4N|g1OjxxYU6=
CCD-112CoN NITPcnZEgXSxdH;4bYNqfHliYYPzZZk> MonaO|IhcHK| Mo[wR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2NFNTFzMlPvUkBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3ME2yMlTPxE1? MlrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OEO4OFIoRjJ5OUizPFQzRC:jPh?=
DU145 NGPnZ4hHfW6ldHnvckBie3OjeR?= NXrabGFrPTBidV2= MmPTOUBpenN? M33sfmlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= NEPRXFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGyNFI2OSd-M{GxNlAzPTF:L3G+
DU145 NWfxbGg5TnWwY4Tpc44h[XO|YYm= NIrGfo02OCC3TR?= NXzDe4RPPSCqcoO= NH\kb5dKdmirYnn0bY9vKG:oIF7hL{9MMyCDVGDhd4UheHWvcDDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDpcpRz[WOnbHz1cIFzKGOjbHPpeY0hdGW4ZXygZZQhPTBidV2gcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nliRoXyZU0zN0GPIHT5[UBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYm= Mn\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=
DU145 M3HYRmZ2dmO2aX;uJIF{e2G7 NV3yVW9HPTBidV2= MXm1JIhzew>? NXTCW3I5UW6qaXLpeIlwdiCxZjDOZUswUytiQWTQZZNmKHC3bYCgbY4hcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClYXzjbZVuKGyndnXsJIF1KDVyIIXNJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IF\1doEuOi:DTTDkfYUh[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5 MlTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=
DU145 NITNPZZHfW6ldHnvckBie3OjeR?= NHvxd2Y2OCC3TR?= MXq1JIhzew>? Moi1TY5pcWKrdHnvckBw\iCQYTuvT{shSVSSYYPlJJB2dXBiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuIHH0JFUxKHWPIH3lZZN2emWmIHHmeIVzKDViaILzJIJ6KE[3cnGtNk9CVSCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7 MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MEK1NUc,OzFzMkCyOVE9N2F-
DU145 NHPWfohHfW6ldHnvckBie3OjeR?= NY\vflNJPTBidV2= M16wW|UhcHK| MUTJcohq[mm2aX;uJI9nKE6jKz;LL{BCXFCjc3WgdJVueCCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxiYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPSCqcoOgZpkhTnW{YT2yM2FOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? M2PFNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
DU145 M1rJcWZ2dmO2aX;uJIF{e2G7 MVe1NEB2VQ>? MYG1JIhzew>? MXfJcohq[mm2aX;uJI9nKE6jKz;LL{BCXFCjc3WgdJVueCCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxiYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPSCqcoOgZpkhTnW{YT2yM2FOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? NXjYdXdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNlAzPTFpPkOxNVIxOjVzPD;hQi=>
DU145 MWjGeY5kfGmxbjDhd5NigQ>? M{ey[|UxKHWP NEX6c3c2KGi{cx?= M3j5fmlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= NGT0dmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGyNFI2OSd-M{GxNlAzPTF:L3G+
DU145 MUPGeY5kfGmxbjDhd5NigQ>? MWC1NEB2VQ>? M3fqUlUhcHK| M1S4W2lvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= MofaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Src / Src / p-EGFR / EGFR / p-STAT3 / STAT3 ; 

PubMed: 25955608     


Analysis of phosphorylated and non-phosphorylated Src, EGFR and STAT3 in A549 cells in a dose-dependent manner. The cancer cells treated with or without various concentrations of digoxin (50, 100, 250 and 500 nM) or 100 nM dasatinib for 24 h were analyzed by Western blot. 

p-PI3K / PI3K / p-AKT / AKT / p-MEK / MEK / p-ERK / ERK / p-FAK / FAK / p-SAPK/JNK / p-Paxillin / Paxillin / p-p130Cas / p130Cas ; 

PubMed: 25955608     


Western blotting analyses of phosphorylated and non-phosphorylated PI3K, AKT, MEK1/2, ERK, FAK, SAPK/JNK, paxillin and p130Cas in (a) A549 cell lines after a 24-h treatment with 100, 250 or 500 nM digoxin. The solvent control was 0.1% DMSO; GAPDH was used as an internal control. 

Nrf2; 

PubMed: 30735911     


Digoxin inhibited the Nrf2 signaling in SW1990/Gem and Panc-1/Gem cells. (A–B) Effects of digoxin on the protein level of Nrf2 in SW1990/Gem and Panc-1/Gem cells. (C–D) Effects of digoxin on the protein level of Nrf2 in SW1990/Gem and Panc-1/Gem cells at different time points.

25955608 30735911
Growth inhibition assay
Cell viability; 

PubMed: 25955608     


Five lung cancer cell lines, (a) A549, (b) H3255, (c) H1975, (d) PC9 and (e) PC9/gef, were treated with 6 different doses (0, 0.01, 0.05, 0.1, 1 and 5 μM) of digoxin at different time points (0, 24, 48, 72 and 96 h), and cell viability was measured using the PrestoBlue Cell Viability reagent after treatment. Quantitative data are presented as the mean±SD (n = 3); *p<0.05 compared with solvent control (0.1% DMSO) at the corresponding time point.

25955608

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL (128.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+corn oil
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 780.94
Formula

C41H64O14

CAS No. 20830-75-5
Storage powder
in solvent
Synonyms N/A
Smiles CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05014087 Not yet recruiting Drug: Intravenous digoxin Acute Alcoholic Hepatitis|Chemical and Drug Induced Liver Injury|Alcohol-Induced Disorders|Steatohepatitis Caused by Ingestible Alcohol Yale University August 2021 Phase 2
NCT03559868 Recruiting Drug: Digoxin|Other: Placebo Inflammatory Response Yale University March 1 2021 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Digoxin (NSC 95100) | Digoxin (NSC 95100) supplier | purchase Digoxin (NSC 95100) | Digoxin (NSC 95100) cost | Digoxin (NSC 95100) manufacturer | order Digoxin (NSC 95100) | Digoxin (NSC 95100) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID